JLJakob Lykke

Jakob Lykke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jakob Lykke has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Changes in psoas muscle area in patients with colorectal cancer three years after surgery: a longitudinal approach

    by Helin Yikilmaz Pardes, Mona Sadek Ali, Troels Gammeltoft Dolin, Casper Simonsen, Lykke Sylow, Jakob Lykke, Jacob Rosenberg, Tinne Laurberg, Louise Lang Lehrskov

    Purpose: The purpose of this study was to investigate long-term changes in psoas muscle area after colorectal cancer (CRC) surgery and their association with preoperative clinical characteristics and mortality. Skeletal muscle loss predicts poor CRC outcomes, but evidence on postoperative changes is limited. Methods: We included 272 patients with localized CRC who underwent elective surgery at Herlev Hospital, Denmark, between 2014 and 2019. Computed tomography (CT) scans before surgery and at three-year follow-up were used to assess psoas muscle area at the L3 vertebral level. Change in muscle area was categorized as > 5% decrease, no change, or > 5% increase. Associations between preoperative clinical characteristics and mortality were analyzed in relation to muscle change. Results: At three-year follow-up after surgery, 39% of patients showed a > 5% decrease in psoas muscle area, 33% had no change, and 28% had a > 5% increase. The results demonstrated that both Union for International Cancer Control (UICC) tumor stage and receipt of adjuvant chemotherapy were independently associated with postoperative changes in psoas muscle area. Among patients who did not receive adjuvant chemotherapy, age was associated with muscle area change, whereas no preoperative clinical characteristics were associated with muscle area change among those receiving adjuvant chemotherapy. Importantly, postoperative longitudinal changes in psoas muscle area were not associated with overall mortality. Conclusion: A considerable proportion of patients with CRC experience long-term loss of psoas muscle area following surgery. These results underscore the variability in postoperative muscle changes and highlight the need for further research to identify high-risk subgroups.

  • Open Access

    Optimized post-discharge care in patients with frailty after colon cancer surgery (project ERAS® 3.0): A protocol for a randomized controlled trial

    by Elna A. Dalsgaard, Troels G. Dolin, Cecilia M. Lund, Jakob Lykke, Tina Munk, Anders Vinther, Jacob Rosenberg


  • The effect of intracorporeal versus extracorporeal anastomosis in robotic right colectomy on perianastomotic perfusion: a substudy to a multicenter RCT

    by Niclas Dohrn, Carolin Oppermann, Helin Yikilmaz, Magnus Laursen, Faisal Khesrawi, Frederik Bjerg Clausen, Henrik Loft Jakobsen, Steffen Brisling, Jakob Lykke, Jens Ravn Eriksen, et al.

    Purpose Previous studies have shown that intracorporeal anastomosis (ICA) in minimally invasive right colectomy may improve postoperative recovery compared with extracorporeal anastomosis (ECA). It has been hypothesized that creating the anastomosis extracorporeally may cause mesenteric traction and compromised intestinal perfusion. The purpose of this study was to investigate the effect of either ICA or ECA on intestinal perfusion. Method This was a substudy to a multicenter, triple-blind randomized clinical trial comparing ICA with ECA in patients undergoing robotic right colectomy for colonic cancer. Videos from intraoperative Indocyanine Green (ICG) fluorescence imaging were analyzed with quantitative ICG perfusion assessment (q-ICG). q-ICG was performed by extracting perfusion metrics from a time-intensity curve generated from an image analysis software: FMAX: maximal fluorescence intensity, TMAX: time until maximal fluorescent signal, T1/2MAX: time until half-maximal fluorescent signal, time ratio (T1/2MAX/TMAX) and slope. Results A total of 68 patients (33 ICA and 35 ECA) were available for analysis. Demographics were similar between the groups, except for mean arterial blood pressure at the time of ICG infusion, which was significantly lower in the ICA group. We found a significantly steeper slope in the ICA group compared to the ECA group (6.3 vs. 4.7 AU/sec, P = .048). There were no significant differences in FMAX, TMAX, T1/2MAX, and time ratio. Conclusion We found evidence of an improved intestinal perfusion following ICA compared with ECA. This finding may be related to patient outcomes and should be explored further in the future. Trial registration. ClinicalTrials.gov NCT03130166.


  • Intracorporeal Versus Extracorporeal Anastomosis in Robotic Right Colectomy

    by Niclas Dohrn, Helin Yikilmaz, Magnus Laursen, Faisal Khesrawi, Frederik Bjerg Clausen, Frederik Sørensen, Henrik Loft Jakobsen, Steffen Brisling, Jakob Lykke, Jens Ravn Eriksen, et al.

    Objective: To determine if minimally invasive right colectomy with intra-corporeal anastomosis improves postoperative recovery compared to extra-corporeal anastomosis. Background: Previous trials have shown that intracorporeal anastomosis improves postoperative recovery; however, it has not yet been evaluated in a setting with optimized perioperative care or with patient-related outcome measures. Methods: This was a multicenter, triple-blind, randomized clinical trial at two high-volume colorectal centers with strict adherence to optimized perioperative care pathways. The patients underwent robotic right colectomy with either intracorporeal or extracorporeal anastomosis. The primary outcome was patient-reported postoperative recovery measured using the “Quality of Recovery–15” questionnaire. ClinicalTrials.gov NCT03130166. Results: A total of 89 patients were randomized and analyzed according to the “Intention-to-treat”-principle. We found no statistically significant differences in patient-reported recovery between the groups. Postoperative pain, nausea, time to ambulation, time to first passage of flatus/stool, length of hospital stay, and pathophysiological tests showed no differences either. The duration of time to create the anastomosis was significantly longer with intracorporeal anastomosis (17 vs 13 min, P = 0.003), while all other intraoperative, postoperative, and pathology variables showed no difference. Conclusion: There were no significant differences in postoperative recovery between the two groups.


  • Open Access

    Identification of Risk Factors Associated With Stage III Disease in Nonmetastatic Colon Cancer: Results From a Prospective National Cohort Study

    by Jakob Lykke, Ole Roikjaer, Per Jess, Jacob Rosenberg, On behalf of the Danish Colorectal Cancer Group

    Purpose: This study aimed to identify possible patient- and tumor-related factors associated with risk of TNM stage III disease in nonmetastatic colon cancer.Methods: The associations between stage III disease and age, sex, lymph node yield, pathological tumor (pT) stage, tumor subsite, type of surgery, and priority of surgery were assessed in a nationwide cohort of 13,766 patients treated with curative resection of colon cancer. Each level of age, lymph node yield, and pT stage was compared to the preceding level.Results: Age, lymph node yield, pT stage, tumor subsite, and priority of surgery were associated with stage III disease. Odds ratios (95% confidence interval [CI]) were as follows: age < 65/65–75 years: 1.28 (95% CI, 1.15–1.43) and 65–75/ > 75 years: 1.22 (95% CI, 1.13–1.32); lymph node yield 0–5/6–11: 0.60 (95% CI, 0.50–0.72), lymph node yield 6–11/12–17: 0.84 (95% CI, 0.76–0.93), and lymph node yield 12–17/ ≥ 18: 0.97 (95% CI, 0.89–1.05); pT1/pT2: 0.74 (95% CI, 0.57–0.95), pT2/pT3: 0.35 (95% CI, 0.30–0.40), and pT3/pT4: 0.49 (95% CI, 0.47–0.54). Only tumors of the transverse colon were independently associated with lower risk of stage III disease than tumors in the sigmoid colon (sigmoid colon: 1, transverse colon: 0.84 [95% CI, 0.73–0.96]; elective surgery: 1, acute surgery: 1.43 [95% CI, 1.29–1.60]).Conclusion: In this study, stage III disease in colon cancer was significantly associated with age, lymph node yield, pT stage, tumor subsite, and priority of surgery but was not associated with right-sided location compared with stage I and II cancers.


  • Open Access

    Lymph node yield and tumour subsite are associated with survival in stage I–III colon cancer: results from a national cohort study

    by On behalf of the Danish Colorectal Cancer Group, Jakob Lykke, Jacob Rosenberg, Per Jess, Ole Roikjaer

    It has been suggested that apart from tumour and nodal status, a range of patient-related and histopathological factors including lymph node yield and tumour location seems to have prognostic implications in stage I–III colon cancer. We analysed the prognostic implication of lymph node yield and tumour subsite in stage I–III colon cancer. Data on patients with stage I to III adenocarcinoma of the colon and treated by curative resection in the period from 2003 to 2011 were extracted from the Danish Colorectal Cancer Group database, merged with information from the Danish National Patient Register and analysed. A total of 13,766 patients were included in the analysis. The 5-year overall survival ranged from 59.3% (95% CI 55.7–62.9%) (lymph node yield 0–5) to 74.0% (95% CI 71.8–76.2%) (lymph node yield ≥ 18) for patients with stage I–II disease (p < 0.0001) and from 36.4% (95% CI 29.8–43.0%) (lymph node yield 0–5) to 59.4% (95% CI 56.6–62.2%) (lymph node yield ≥ 18) for patients with stage III disease (p < 0.0001). The 5-year overall survival for tumour side left/right was 59.3% (95% CI 57.9–60.7%)/64.8% (CI 63.4–66.2%) (p < 0.0001). In the seven colonic tumour subsites, the 5-year overall survival ranged from 56.6% (95% CI 51.8–61.4%) at splenic flexure to 65.8% (95% CI 64.5–67.2%) in the sigmoid colon (p < 0.0001). In a cox regression analysis, lymph node yield and tumour side right/left were found to be prognostic factors. Tumours at the hepatic and splenic flexures had an adverse prognostic outcome. For stage I–III colon cancer, a lymph node yield beyond the recommended 12 lymph nodes was associated with improved survival. Both subsite in the right colon, as well as subsite in the left colon, turned out with adverse prognostic outcome questioning a simple classification into right-sided and left-sided colon cancer.


  • A high lymph node yield in colon cancer is associated with age, tumour stage, tumour sub-site and priority of surgery. Results from a prospective national cohort study

    by On behalf of the Danish Colorectal Cancer Group, Jakob Lykke, Per Jess, Ole Roikjær

    Aim To determine the relation between patient-related and histopathological factors, as well as the influence of national programs for diagnosing and treatment of colon cancer and a lymph node yield (LNY) ≥ 12. Method An analysis was carried out of the LNY in a nationwide Danish cohort treated by curative resection of stage I–III colon cancer in the period 2003–2011. The association between a LNY ≥ 12 and age, sex, body mass index, open vs. laparoscopic surgery, acute vs. elective surgery, pT stage, tumour sub-site and year of diagnosis was analysed. Results A total of 13,766 patients were eligible for the analysis. In total, 71.4 % of the patients had a LNY ≥ 12. In multivariate analysis, age, pT stage, tumour sub-site and priority of surgery were independently associated with the probability of a LNY ≥ 12. Odds ratios (ORs) were as follows: age 75 0.517 (CI 0.439–0.609); T1 1, T2 2.750 (CI 2.168–3.487), T3 6.016 (CI 4.879–7.418), T4 6.317 (CI 4.950–8.063); right colon 1, left colon 0.568 (0.511–0.633); elective surgery 1, acute surgery 0.748 (CI 0.625–0.894). Moreover, year of diagnosis was associated with the probability of a LNY ≥ 12: OR 1.480 (CI 1.445–1.516) for each increasing year in the study period. Conclusion A LNY ≥ 12 is significantly associated with age, pT stage, tumour sub-site and priority of surgery. A significant increase in the LNY over the period of the study was observed, probably reflecting the effect of national programmes initiated by the Danish Colorectal Cancer Group.


  • A minimum yield of twelve lymph nodes in rectal cancer remains valid in the era of neo-adjuvant treatment

    by On behalf of the Danish Colorectal Cancer Group, Jakob Lykke, Per Jess, Ole Roikjaer

    The purpose of the study was to examine if a minimum of 12 lymph nodes (LNs) is still valid in rectal cancer after neo-adjuvant treatment. An analysis was carried out in a nationwide Danish cohort of 6793 patients, treated by curative resection of stage I–III rectal cancer during the period 2003–2011. The cohort was divided into two groups according to whether neo-adjuvant treatment had been given. The groups were analysed separately and were further analysed according to four lymph node yield (LNY) groups 0–5, 6–11, 12–17 and ≥18. Two thousand one hundred twenty-three patients (31.0 %) received neo-adjuvant treatment. A median LNY of 10 and 15 (p < 0.0001) and rates of node-positive (N-positive) disease of 31.6 and 36.7 % (p < 0.001) were observed with and without (+/−) neo-adjuvant treatment, respectively. The rate of N-positive disease according to tumour stage ranged from 4.8 %/11.4 % (ypT0/pT1) to 42.1 %/64.1 % (ypT4/pT4). The rate of N-positive disease according to LNY ranged from 19.5 %/16.8 % (0–5 LNs) to 42.6 %/37.9 % (≥18 LNs) (−/+neo-adjuvant treatment). In a logistic regression analysis, a significant association was found between N-positive disease and pT/ypT stage as well as between N-positive disease and LNY. A significantly smaller ratio of N-positive disease was observed in the group of patients who had received neo-adjuvant treatment. The ratio of N-positive disease increased significantly with more advanced tumour stage and increasing LNY irrespective of neo-adjuvant treatment. A minimum of 12 LNs is needed to ensure N-negative disease, irrespective of neo-adjuvant treatment.


  • Tumour stage and preoperative chemoradiotherapy influence the lymph node yield inStagesI–IIIrectal cancer: results from a prospective nationwide cohort study

    by J. Lykke, O. Roikjær, P. Jess, the Danish Colorectal Cancer Group

    Aim: The study aimed to determine whether the lymph node yield (LNY) in rectal cancer is influenced by patient‐related and histopathological factors and the use of preoperative chemoradiotherapy (CRT).Method: An analysis was carried out of theLNYin a nationwideDanish cohort of 7950 patients, treated by curative resection ofStageI–IIIrectal cancer during the period 2001–2011. The impact of year of diagnosis, age, gender, pathological stage of the tumour (pT‐stage) and preoperativeCRTonLNYwas analysed.Results: Twenty‐nine per cent of the patients received preoperativeCRT. The medianLNYwas 13 [interquartile range (IQR): 8–19]. A total of 43.4% of the patients had anLNYof < 12. The medianLNYincreased from 8 (IQR: 5–12) to 20 (IQR: 13–28)LNs over the years of the study period (P < 0.0001). Gender and body mass index (BMI) had no impact on the medianLNY. Age had a minor impact, with a range of 12 (IQR: 8–18) to 13 (IQR: 9–20) (P < 0.0001). TheLNYranged from 9 (IQR: 6–14) to 16 (IQR: 10–26), according to pT‐stage (pT0–pT4) (P < 0.0001). MedianLNY, according to preoperativeCRTor no preoperativeCRT, was 10 (IQR: 6–16) and 14 (IQR: 8–18), respectively (P < 0.0001). The percentages of patients with anLNYof < 12, according to preoperativeCRTor no preoperativeCRT, were 58.7% and 37.1%, respectively (P < 0.0001).Conclusion: An increase in theLNYover the period of the study was observed, probably reflecting improved quality of surgery and histopathology. A minor significant reduction ofLNYwas found with increasing age of the patient.LNYwas significantly related to pT‐stage and to the use of preoperative chemoradiotherapy. For these reasons the minimum harvest of 12LNs as a surrogate marker for the oncological quality of surgery should be questioned.